Literature DB >> 35224019

Stopping Anti-TNF in CD Remitters: Cons.

Taku Kobayashi1.   

Abstract

Crohn's disease may cause a life-long disease burden in many aspects due to its progressive nature. A large proportion of refractory patients have been benefiting from scheduled maintenance anti-TNF treatment; therefore, strategy to stop anti-TNF agents in Crohn's disease is not widely conducted. There have been observational studies demonstrating that approximately half of the patients relapse within a year after discontinuation. Several factors have been suggested as potential predictors for relapse; however, a consensus has not been reached so far. Although most relapse can be rescued by the re-treatment with the same anti-TNF agent, a proportion of patients may result in progressive bowel damage and the need for surgery. Therefore, an attempt to stop anti-TNF is not recommended without careful discussion, even if they are in long-term remission.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Adalimumab; Crohn's disease; De-escalation; Inflammatory bowel disease; Infliximab

Year:  2021        PMID: 35224019      PMCID: PMC8820156          DOI: 10.1159/000517961

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  46 in total

1.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

Authors:  W A Faubion; E V Loftus; W S Harmsen; A R Zinsmeister; W J Sandborn
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

2.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors:  Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 3.  Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Laurent Peyrin-Biroulet; Gert Van Assche; David Gómez-Ulloa; Laura García-Álvarez; Núria Lara; Chris M Black; Sumesh Kachroo
Journal:  Clin Gastroenterol Hepatol       Date:  2016-07-05       Impact factor: 11.382

4.  Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.

Authors:  S Ben-Horin; Y Chowers; B Ungar; U Kopylov; R Loebstein; B Weiss; R Eliakim; E Del Tedesco; S Paul; X Roblin
Journal:  Aliment Pharmacol Ther       Date:  2015-06-01       Impact factor: 8.171

5.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

7.  Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.

Authors:  Hirotsugu Imaeda; Shigeki Bamba; Kenichiro Takahashi; Takehide Fujimoto; Hiromitsu Ban; Tomoyuki Tsujikawa; Masaya Sasaki; Yoshihide Fujiyama; Akira Andoh
Journal:  J Gastroenterol       Date:  2013-05-11       Impact factor: 7.527

8.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Authors:  Corey A Siegel; Sadie M Marden; Sarah M Persing; Robin J Larson; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2009-01-24       Impact factor: 11.382

9.  Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.

Authors:  A J Brooks; S Sebastian; S S Cross; K Robinson; L Warren; A Wright; A M Marsh; H Tsai; F Majeed; M E McAlindon; C Preston; P J Hamlin; A J Lobo
Journal:  J Crohns Colitis       Date:  2017-12-04       Impact factor: 9.071

Review 10.  Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.

Authors:  N A Kennedy; B Warner; E L Johnston; L Flanders; P Hendy; N S Ding; R Harris; A S Fadra; C Basquill; C A Lamb; F L Cameron; C D Murray; M Parkes; I Gooding; T Ahmad; D R Gaya; S Mann; J O Lindsay; J Gordon; J Satsangi; A Hart; S McCartney; P Irving; C W Lees
Journal:  Aliment Pharmacol Ther       Date:  2016-02-19       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.